Literature DB >> 29435325

Psychological distress, iron deficiency, active disease and female gender are independent risk factors for fatigue in patients with ulcerative colitis.

Börje Jonefjäll1,2, Magnus Simrén1,3, Anders Lasson4, Lena Öhman1,5,6, Hans Strid1,4.   

Abstract

BACKGROUND: Patients with ulcerative colitis often report fatigue.
OBJECTIVES: To investigate prevalence of and risk factors for fatigue in patients with ulcerative colitis with active disease and during deep remission.
METHODS: In this cross-sectional study, disease activity was evaluated with endoscopy and calprotectin, and patients were classified as having active disease (n = 133) or being in deep remission (n = 155). Blood samples were analysed to assess anaemia, iron deficiency and systemic immune activity. Patients completed questionnaires to assess fatigue, psychological distress, gastrointestinal symptoms and quality of life.
RESULTS: The prevalence of high fatigue (general fatigue ≥ 13, Multidimensional Fatigue Inventory) was 40% in the full study population. Among patients with high fatigue, female gender and iron deficiency were more prevalent, and these patients had more severe disease activity and reported higher levels of anxiety, depression and decreased quality of life compared with patients with no/mild fatigue. A logistic regression analysis identified probable psychiatric disorder (odds ratio (OR) (confidence interval) 6.1 (3.1-12.2)), iron deficiency (OR 2.5 (1.2-5.1)), active disease (OR 2.2 (1.2-3.9)) and female gender (OR 2.1 (1.1-3.7)) as independent risk factors for high fatigue. Similar results were found concerning psychological distress, gender and quality of life, but immune markers did not differ in patients in deep remission with high vs. no/mild fatigue.
CONCLUSIONS: Probable psychiatric disorder, iron deficiency, active disease and female gender are independent risk factors for high fatigue in patients with ulcerative colitis. Low-grade immune activity does not seem to be the cause of fatigue among patients in deep remission.

Entities:  

Keywords:  Ulcerative colitis; fatigue; inflammation; inflammatory bowel disease; iron deficiency; psychiatric disease

Year:  2017        PMID: 29435325      PMCID: PMC5802665          DOI: 10.1177/2050640617703868

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  40 in total

1.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study.

Authors:  A G Røseth; M K Fagerhol; E Aadland; H Schjønsby
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

2.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

3.  Chronic fatigue is more prevalent in patients with inflammatory bowel disease than in healthy controls.

Authors:  Lars-Petter Jelsness-Jørgensen; Tomm Bernklev; Magne Henriksen; Roald Torp; Bjørn A Moum
Journal:  Inflamm Bowel Dis       Date:  2010-11-08       Impact factor: 5.325

4.  Classification of inflammatory bowel disease.

Authors:  J E Lennard-Jones
Journal:  Scand J Gastroenterol Suppl       Date:  1989

5.  Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors.

Authors:  Magnus Simrén; Jenny Axelsson; Rolf Gillberg; Hasse Abrahamsson; Jan Svedlund; Einar S Björnsson
Journal:  Am J Gastroenterol       Date:  2002-02       Impact factor: 10.864

6.  Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens?

Authors:  E Dimenäs; H Glise; B Hallerbäck; H Hernqvist; J Svedlund; I Wiklund
Journal:  Scand J Gastroenterol       Date:  1993-08       Impact factor: 2.423

Review 7.  Review article: Description and management of fatigue in inflammatory bowel disease.

Authors:  W Czuber-Dochan; E Ream; C Norton
Journal:  Aliment Pharmacol Ther       Date:  2013-01-13       Impact factor: 8.171

8.  Changes in fatigue over 2 years are associated with activity of inflammatory bowel disease and psychological factors.

Authors:  Lesley A Graff; Ian Clara; John R Walker; Lisa Lix; Rachel Carr; Norine Miller; Linda Rogala; Charles N Bernstein
Journal:  Clin Gastroenterol Hepatol       Date:  2013-04-16       Impact factor: 11.382

9.  Fatigue interference with daily living among patients with inflammatory bowel disease.

Authors:  Randi Opheim; May Solveig Fagermoen; Tomm Bernklev; Lars-Petter Jelsness-Jorgensen; Bjorn Moum
Journal:  Qual Life Res       Date:  2013-08-23       Impact factor: 4.147

Review 10.  Fatigue in chronic inflammation - a link to pain pathways.

Authors:  Karine Louati; Francis Berenbaum
Journal:  Arthritis Res Ther       Date:  2015-10-05       Impact factor: 5.156

View more
  9 in total

1.  Relationship Between Endoscopic and Clinical Disease Activity With Fatigue in Inflammatory Bowel Disease.

Authors:  Kendra J Kamp; Kindra Clark-Snustad; Mitra Barahimi; Scott Lee
Journal:  Gastroenterol Nurs       Date:  2022 Jan-Feb 01       Impact factor: 0.978

2.  Prevalence and factors associated with fatigue in patients with ulcerative colitis in China: a cross-sectional study.

Authors:  Feng Xu; Jingyi Hu; Qian Yang; Yuejin Ji; Cheng Cheng; Lei Zhu; Hong Shen
Journal:  BMC Gastroenterol       Date:  2022-06-03       Impact factor: 2.847

3.  Randomized controlled trial: a pilot study of a psychoeducational intervention for fatigue in patients with quiescent inflammatory bowel disease.

Authors:  Anthony O'Connor; Raguprakash Ratnakumaran; Lisa Warren; Debbie Pullen; Anna Errington; David J Gracie; Rebecca C Sagar; P John Hamlin; Alexander C Ford
Journal:  Ther Adv Chronic Dis       Date:  2019-03-26       Impact factor: 5.091

4.  Anti-TNF-α Monoclonal Antibody Therapy Improves Anemia through Downregulating Hepatocyte Hepcidin Expression in Inflammatory Bowel Disease.

Authors:  Weigang Shu; Zhi Pang; Chunjin Xu; Jian Lin; Gengfeng Li; Wei Wu; Suofeng Sun; Junxiang Li; Xiuling Li; Zhanju Liu
Journal:  Mediators Inflamm       Date:  2019-11-13       Impact factor: 4.711

Review 5.  Fatigue in Inflammatory Bowel Diseases: Etiologies and Management.

Authors:  Angelica Nocerino; Andrew Nguyen; Manasi Agrawal; Anjali Mone; Komal Lakhani; Arun Swaminath
Journal:  Adv Ther       Date:  2019-11-23       Impact factor: 3.845

6.  Fatigue in patients with inflammatory bowel disease in Eastern China.

Authors:  Shan-Shan Gong; Yi-Hong Fan; Bin Lv; Mie-Qing Zhang; Yi Xu; Jing Zhao
Journal:  World J Gastroenterol       Date:  2021-03-21       Impact factor: 5.742

7.  Health-related quality of life in patients with long-standing ulcerative colitis in remission.

Authors:  Georgios Mavroudis; Magnus Simrén; Lena Öhman; Hans Strid
Journal:  Therap Adv Gastroenterol       Date:  2022-02-11       Impact factor: 4.409

8.  Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study.

Authors:  Talat Bessissow; Geoffrey C Nguyen; Osman Tarabain; Laurent Peyrin-Biroulet; Nathalie Foucault; Kevin McHugh; Joannie Ruel
Journal:  World J Gastroenterol       Date:  2022-09-14       Impact factor: 5.374

9.  Proteomic analyses do not reveal subclinical inflammation in fatigued patients with clinically quiescent inflammatory bowel disease.

Authors:  Arno R Bourgonje; Sietse J Wichers; Shixian Hu; Hendrik M van Dullemen; Marijn C Visschedijk; Klaas Nico Faber; Eleonora A M Festen; Gerard Dijkstra; Janneke N Samsom; Rinse K Weersma; Lieke M Spekhorst
Journal:  Sci Rep       Date:  2022-08-26       Impact factor: 4.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.